A unique industrial - Academic collaboration towards the next generation of schizophrenia therapeutics

Current Topics in Medicinal Chemistry

Volumn 14, Issue 3, 2014, Pages 304-312

  Macdonald, Gregor J ^a   Lindsley, Craig W ^b,c  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VANDERBILT UNIVERSITY   (United States)

Author keywords

Allosteric; Glutamate; Metabotropic; NMDA hypofunction; Positive allosteric modulator; Schizophrenia

Indexed keywords

CLOZAPINE; G PROTEIN COUPLED RECEPTOR; HALOPERIDOL; METABOTROPIC RECEPTOR; MUSCARINIC RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROLEPTIC AGENT; POMAGLUMETAD METHIONIL; UNCLASSIFIED DRUG; WO 2008151184; WO 2011035324; WO 2011073339; WO 2011073347; WO 2011148863; WO 2012031024; WO 2012078817; WO 2012092530; WO 201209782; WO 2012125732; WO 202083224;

ARTICLE; DRUG BINDING; DRUG DESIGN; DRUG EFFICACY; DRUG SYNTHESIS; HUMAN; MOLECULAR DOCKING; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROCESS OPTIMIZATION; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

ACADEMIES AND INSTITUTES; DRUG DISCOVERY; DRUG INDUSTRY; HUMANS; LABORATORIES; SCHIZOPHRENIA;

EID: 84894099648     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026613666131127154443     Document Type: Article

References (84)

1. Sherer, T.B. Money without collaboration won't bring cures'. Nature Med., 2013, 19, 127.
2. Lindsley, C.W.; MacDonald, G. Development of novel reagents for the treatment of Schizophrenia. 243rd ACS National Meeting, San Diego, CA, March 29, 2012.
3. Raedler, T.J.; Bymaster, F.P.; Tandon, R. Towards a muscarinic hypothesis of schizophrenia. Mol. Psychiatry, 2007, 12, 232-246.
4. Goldberg, T.E.; Gold, J.M. Contrasts between patients with affective disorders and patients with schizophrenia on a neuropsychological test battery. Am. J. Psychiatry, 1993, 150, 1355-1362.
5. Meltzer, H.Y. Treatment of schizophrenia and spectrum disorders: pharmacotherapy, psychosocial treatments, and neurotransmitter interactions. Biol. Psychiatry, 1999, 46, 1321-1327.
6. Weickert, T.W.; Goldberg, T.E.; Gold, J.M. Cognitive impairments in patients with schizophrenia displaying preserved and compromised intellect. Arch. Gen. Psychiatry, 2007, 57, 907-913.
7. Siris, S.G. Schizophrenia. Blackwell Science Ltd. Oxford, 1995, pp. 128-146.
8. Green M.F. New possibilities for cognition enhancement in schizophrenia. Am. J. Psychiatry, 2009, 166, 321-330.
9. Carlsson, A. The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology, 1988, 1, 179-186.
10. Conn, P.J.; Tamminga, C.; Schoepp, D.D.; Lindsley, C.W. Schizophrenia: Moving Beyond Monoamine Antagonists. Mol. Intervent., 2008, 8, 99-105.
11. Nikam, S.S.; Awasthi, A.K. Evolution of schizophrenia drugs: a focus on dopaminergic systems. Curr. Opin. Investig. Drugs, 2008, 9, 37-46.
12. Toda, M.; Abi-Dargham, A. Dopamine hypothesis of schizophrenia: making sense of it all. Curr. Psychiatry Rep., 2007, 9, 329-336.
13. Saha, S.; Chant, D.; Welham, J.; McGrath, J. A systematic review of the prevalence of schizophrenia. PLoS Med., 2005, 2, e141.
14. Vinson, P.N.; Conn, P.J. Metabotropic glutamate receptors as therapeutic targets for schizophrenia. Neuropharmacology, 2012, 62, 1461-1472.
15. Kantrowitz, J.; Javitt, D.C. Glutamatergic transmission in schizophrenia: from basic research to clinical practice. Curr. Opin. Psychiatry, 2012, 25, 96-102.
16. Moghaddam, B.; Javitt, D.C. From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment. Neuropsychopharmacology, 2012, 37, 4-15.
17. Lindsley, C.W.; Shipe, W.D.; Wolkenberg, S.E.; Theberge, C.R.; Williams, D.L. Jr.; Sur, C.; Kinney, G.G. Progress towards validating the NMDA receptor hypofunction hypothesis of schizophrenia. Curr. Topics Med. Chem., 2006, 8, 771-784.
18. Javitt D.C. Glutamatergic theories of schizophrenia. Isr. J. Psychiatry Relat. Sci., 2010, 47, 4-16.
19. Menniti, F.S.; Lindsley, C.W.; Conn, P.J.; Pandit, J.; Zagouras, P.; Volkmann, R.A. Allosteric modulation for the treatment of schizophrenia: Targeting glutamatergic Networks. Curr. Topics Med. Chem., 2013, 13, 26-54.
20. Conn, P.J.; Lindsley, C.W.; Jones, C. Allosteric modulation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia. Trends in Pharm. Sci., 2009, 30, 25-31.
21. Bridges, T.M.; Williams, R.; Lindsley, C.W. Design of potent GlyT1 inhibitors: In vitro and In vivo profiles. Curr. Opin. Mol. Ther., 2008, 10, 591-604.
22. Lindsley, C.W.; Wolkenberg, S.E.; Kinney, G.G. Progress in the preparation and testing of glycine transporter type-1 (GlyT1) inhibitors. Curr. Topics Med. Chem., 2006, 8, 1883-1894.
23. Wolkenberg, S.E. and Sur, C. Recent progress in the discovery of non-sarcosine based GlyT1 inhibitors. Curr. Topics Med. Chem., 2010, 10, 170-186.
24. Hashimoto, K. Glycine transporter-1: A new potential therapeutic target for schizophrenia. Curr. Pharm. Design., 2011, 17, 112-120.
25. Alberati, D.; Moreau, J.L.; Lengyel, J.; Hauser, N.; Mory, R.; Borroni, E.; Pinard, E.; Knoflach, F.; Schlotterbeck, G.; Hainzl, D.; Wettstein, J.G. Glycine reuptake inhibitor RG1678: a pharmacologic characterization of an investigational agent for the treatment of schizophrenia. Neuropharmacology, 2012, 62, 1152-1161.
26. Meltzer, M.; Geneste, H.; Gault, L.; Marek, G.J. LY-2140023, a prodrug of the group II metabotropic glutamate receptor agonist LY-404039 for the potential treatment of schizophrenia. Curr. Opin. Investig. Drugs, 2010, 11, 833-845.
27. For trial details see: http://clinicaltrials.gov/show/NCT01307800.
28. Sheffler, D.J.; Pinkerton, A.B.; Dahl, R.; Markou, A.; Cosford, N.D.P. Recent progress in the synthesis and characterization of group II metabotropic glutamate receptor allosteric modulators. ACS Chem. Neurosci., 2011, 2, 382-393.
29. Conn, P.J.; Jones, C.; Lindsley, C.W. Subtype selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders. Trends Pharm. Sci., 2009, 30, 148-156.
30. Bridges, T.M.; LeBois, E.P.; Hopkins, C.R.; Wood, M.R.; Jones, J.K.; Conn, P.J.; Lindsley, C.W. Antipsychotic potential of muscarinic allosteric modulation. Drug News Perspect., 2010, 23, 229-240.
31. Williams, D.L. Jr. Lindsley, C.W. Positive allosteric modulators of metabotropic glutamate receptor subtype 5 (mGluR5). Curr. Topics Med. Chem., 2005, 5, 825-838.
32. Lindsley, C.W.; Wolkenberg, S.E.; Shipe, W.; Williams, D.L. Jr. Recent advances in positive allosteric modulators of metabotropic glutamate receptors (mGluRs). Curr. Opin. Drug Disc. Dev., 2005, 8, 449-457.
33. Chavez-Noriega, L.E.; Marino, M.J.; Schaffhauser, H.; Campbell, U.C.; Conn, P.J. Novel potential therapeutics for schizophrenia: focus on the modulation of metabotropic glutamate receptor function. Curr. Neuropharmacol., 2005, 1, 9-34.
34. Marino, M.J.; Conn, P.J. Direct and indirect modulation of the Nmethyl D-aspartate receptor. Curr. Drug Targets CNS Neurol. Disord., 2002, 1, 1-16.
35. Chavez-Noriega, L.E.; Schaffhauer, H.; Campbell, U.C. Metabotropic glutamate receptors: potential drug targets for the treatment of schizophrenia. Curr. Drug Targets CNS Neurol. Disord., 2002, 1, 261-281.
36. Cartnell, J.; Schoepp, D.D. Regulation of neurotransmitter release by metabotropic glutamate receptors. J. Neurochem., 2000, 75, 889-907.
37. Conn, P.J.; Pin, J.P. Pharmacology and functions of metabotropic glutamate receptors. Ann. Rev. Pharmacol. Toxicol., 1997, 37, 205-237.
38. Schoepp, D.D.; Jane, D.E.; Monn, J.A. Pharmacological agents acting at subtypes of metabotropic glutamate receptors. Neuropharmacology, 1999, 38, 1431-1476.
39. Stauffer SR. Progress toward positive allosteric modulators of metabotropic glutamate receptor subtype 5 (mGlu5). ACS Chem. Neurosci., 2011, 2, 450-470.
40. Smith, N.J.; Bennett, K.A.; Milligan, G. When simple agonism is not enough: Emerging modalities of GPCR ligands. Mol. and Cell Endocr., 2011, 331, 241-247.
41. Melancon, B.J.; Hopkins, C.R.; Wood, M.R.; Emmitte, K.A.; Niswender, C.M.; Christopoulos, A.; Conn, P.J.; Lindsley, C.W. Allosteric Modulation of 7 Transmembrane Spanning Receptors: Theory, Practice and Opportunities for CNS Drug Discovery. J. Med. Chem., 2012, 55, 1445-1464.
42. Conn, P.J.; Christopolous, A.; Lindsley, C.W. Allosteric Modulators of GPCRs as a Novel Approach to Treatment of CNS Disorders. Nat. Rev. Drug Discov., 2009, 8, 41-54.
43. Conn, P.J.; Lindsley, C.W.; Jones, C. Allosteric modulation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia. Trends in Pharm. Sci., 2009, 30, 25-31.
44. Lewis, J.A.; Lebois, E.P.; Lindsley, C.W. Allosteric modulators of kinases and GPCRs. Design principles and structural diversity. Curr. Opin. Chem. Biol., 2008, 12, 269-279.
45. Jensen, A.A.; Spalding, T.A. Allosteric modulation of G-protein coupled receptors. Euro. J. Pharm. Sci., 2004, 21, 407-420.
46. Christopoulos A. Allosteric binding sites on cell-surface receptors: novel targets for drug discovery. Nat. Rev. Drug Disc., 2001, 1, 198-215.
47. Bridges, T.M.; Lindsley, C.W. G-protein coupled receptors: From classical modes of modulation to allosteric mechanisms. ACS Chem. Biol., 2008, 3, 530-542.
48. Kew, J.N.C. Positive and negative allosteric modulation of metabotropic glutamate receptors: emerging therapeutic potential. Pharm. Ther., 2004, 104, 233-244.
49. Sharma, S.; Rodriguez, A; Conn, P.J.; Lindsley, C.W. Synthesis and SAR of a mGluR5 allosteric partial antagonist lead: Unexpected modulation of pharmacology with slight structural modifications to a 5-(phenylethynyl)pyrimidine scaffold. Bioorg. Med. Chem. Lett., 2008, 18, 4098-4101.
50. Sharma, S.; Kedrowski, J.; Rook, J.M.; Smith, J.M.; Jones, C.K.; Rodriguez, A.L.; Conn, P.J.; Lindsley, C.W. Discovery of Molecular Switches that Modulate Modes of mGluR5 Pharmacology In vitro and In vivo Within a Series of Functionalized 5- (phenylethynyl) pyrimidines. J. Med. Chem., 2009, 52, 4103-4106.
51. Wood, M.R.; Hopkins, C.R.; Brogan, J.T.; Conn, P.J.; Lindsley, C.W. 'Molecular switches' on allosteric ligands that modulate modes of pharmacology. Biochemistry, 2011, 50, 2403-2410.
52. Sheffler, D.J.; Wenthur, C.J.; Bruner, J.A.; Carrington, S.J.S.; Blobaum, A.L.; Morrison, R.D.; Daniels, J.S.; Niswender, C.M.; Conn, P.J.; Lindsley, C.W. Development of a novel, CNS penetrant metabotropic glutamate receptor 3 (mGlu3) NAM probe (ML289) derived from a closely related mGlu5 PAM' Bioorg. Med. Chem. Lett., 2012, 22, 3921-3925.
53. Zhang, Y.; Rodriguez, A.L.; Conn, P.J. Allosteric potentiators of metabotropic glutamate receptor subtype 5 have differential effects on different signaling pathways in cortical astrocytes. J. Pharmacol. Exp. Ther., 2008, 315, 1212-1219.
54. Rocheville, M.; Garland, S.L. An industrial perspective on positive allosteric modulation as a means to discover safe and selective drugs. Drug Discov. Today: Technol., 2010, 7, e87-e94.
55. Gasparini, F.; Lingenhohl, K.; Stoehr, N.; Flor, P.J.; Heinrich, M.; Vranesic, I.; Biollaz, M.; Allgeier, H.; Heckendorn, R.; Urwyler, S.; Varney, M.A.; Johnson, E.C.; Hess, S.D.; Rao, S.P.; Sacaan, A.I.; Santori, E.M.; Velicelebi, G.; Kuhn, R. 2-Methyl-6- (phenylethynyl)- pyrimidine (MPEP), a potent, selective and systemically active mGluR5 receptor antagonist. Neuropharmacology, 1999, 38, 1493-1503.
56. O'Brien, J.A.; Lemaire, W.; Chen, T-B.; Chang, R.S.L.; Jacobson, M.A.; Ha, S.N.; Lindsley, C.W.; Sur, C.; Pettibone, D.J.; Conn, J.; Wiliams, D.L. A family of highly selective allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5). Mol. Pharmacol., 2003, 64 (3), 731-741.
57. O'Brien, J.A.; Lemaire, W.; Wittmann, M.; Jacobson, M.A.; Ha, S.N.; Wisnoski, D.D.; Lindsley, C.W.; Schaffhauser, H.J.; Sur, C.; Duggan, M.E.; Pettibone, D.J.; Conn, J.; Williams, D.L. A novel selective allosteric modulator potentiates the activity of the native metabotropic glutamate receptor subtype 5 (mGluR5) in rat forebrain. J. Pharmacol. Exp. Therapeut., 2004, 309(2), 568-579.
58. Zhao, Z.; Wisnoski, D.D.; O'Brien, J.A.; Lemiare, W.; Williams, Jr., D.L.; Jacobson, M.A.; Wittman, M.; Ha, S.; Schaffhauser, H.; Sur, C.; Pettibone, D.J.; Duggan, M.E.; Conn, P.J.; Hartman, G.D.; Lindsley, C.W. Challlenges in the development of mGluR5 positive allosteric modulators: the discovery of CPPHA. Bioorg. Med. Chem.Lett., 2007, 17, 1386-1389.
59. Noetzel, M.J.; Gregory, K.J.; Vinson, J.T.; Manka, S.R.; Stauffer, S.R.; Daniels, S.J.; Lindsley, C.W.; Niswender, C.M.; Xiang, Z.; Conn, P.J. 'A novel metabotropic glutamate receptor 5 positive allosteric modulator acts at a unique site and confers stimulus bias to mGlu5 signaling' Mol. Pharm., 2013, 83, 835-847.
60. Lindsley, C.W.; Wisnoski, D.D.; Leister, W.H.; O'Brien, J.A.; Lemiare, W.; Williams, Jr., D.L.; Burno, M.; Sur, C.; Kinney, G.G.; Pettibone, D.J.; Tiller, P.R.; Smith, S.; Duggan, M.E.; Hartman, G.D.; Conn, P.J.; Huff, J.R. Discovery of positive allosteric modulators for the metabotropic glutamate receptor subtype 5 from a series of N-(1,3- Diphenyl-1H-pyrazol-5- yl)benzamides that potentiate receptor function In vivo' J. Med. Chem., 2004, 47, 5825-5828.
61. Kinney, G.G.; O'Brien, Lemaire, W.; Burno, M.' Bickel, D.J.; Clements, M.K.; Wisnoski, D.D.; Lindsley, C.W.; Tiller, P.R.; Smith, S.; Jacobson, M.A.; Sur, C.; Duggan, M.E.; Pettibone, D.J.; Williams, Jr., D.W. 'A novel selective allosteric modulator of metabotropic glutamate receptor subtype 5 (mGluR5) has an antipsychotic profile in rat behavioral models' J. Pharmacol. Exp. Therapeut., 2005, 313(1), 199-208.
62. Liu, F.; Grauer, S.; Kelley, C.; Navarra, R.; Graf, R.; Zhang, G.; Atkinson, P.J.; Wantuch, C.; Popiolek, M.; Day, M.; Khawaja, X.; Smith, D.; Olsen, M.; Kouranova, E.; Gilbert, A.; Lai, M.; Pausch, M.H.; Pruthi, F.; Pulcicchio, C.; Brandon, N.J.; Comery, T.A.; Beyer, C.E.; Logue, S.; Rosenzweig-Lipson, S.; Marquis, K.L. ADX47273 [S-(4-Fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]- oxadiazol-5-yl]-piperidin-1-yl}-methanone]:A Novel Metabotropic Glutamate Receptor 5-Selective Positive Allosteric Modulator with Preclinical Antipsychotic-Like and Procognitive Activities. J. Pharmacol. & Exp. Ther., 2008, 327, 827-839.
63. Engers, D.W.; Rodriguez, A.L.; Oluwatola, O.; Hammond, A.S.; Venable, D.F.; Williams, R.; Sulikowski, G.A.; Conn, P.J.; Lindsley, C.W. Synthesis, SAR and unanticipated Pharmacological profiles of analogs of the mGluR5 ago-potentiator ADX-47273. ChemMedChem., 2009, 4, 505-511.
64. Lamb, J.A.; Engers, D.W.; Niswender, C.M.; Venable, D.; Conn, P.J.; Lindsley, C.W. Discovery of molecular switches within the ADX-47273 mGlu5 PAM scaffold that modulate modes of pharmacology to afford potent mGlu5 NAMs, PAMs, and partial antagonists. Bioorg. Med. Chem. Lett., 2011, 21, 2711-2714.
65. Lindsley, C.W.; Stauffer, S.R. 'Metabotropic glutamate receptor 5 (mGlu5) positive allosteric modulators (PAMs) for the treatment of schizophrenia: An historical perspective and a review of the patent literature' Pharm. Patent Anal., 2013, 2, 93-108.
66. For information on the Vanderbilt Center for Neuroscience Drug Discovery (VCNDD) see: www.vcndd.com.
67. Rodriguez, A.L.; Grier, M.D.; Jones, C.K.; Herman, E.J.; Kane, A.S.; Smith, R.L.; Williams, R.; Zhou, Y.; Marlo, J.E.; Days, E.L.; Blatt, T.N.; Jadhav, S.; Menon, U.; Vinson, P.N.; Rook, J.M.; Stauffer, S.R.; Niswender, C.M.; Lindsley, C.W.; Weaver, C.D.; Conn, P.J. 'Discovery of novel allosteric modulators of metabotropic glutamate receptor subtype 5 reveals chemical and functional diversity and In vivo activity in rat behavioral models of anxiolytic and antipsychotic activity. Mol. Pharm., 2010, 78, 1105-1123.
68. For information on Janssen see: http://www.janssenpharmaceuticalsinc.com.
69. Wang, S.S.J & J Vanderbilt Team Up on Schizophrenia Drugs. The Wall Street Journal, January 8, 2009.
70. Zhou, Y.; Manka, J.; Rodriguez, A.L.; Weaver, C.D.; Jones, C.K.; Conn, P.J.; Lindsley, C.W.; Stauffer, S.R. N-Aryl piperazines as selective mGlu5 potentiators with improved Physiochemical properties and efficacy in a rodent model predictive of antipsychotic Activity. ACS Med. Chem. Lett., 2010, 1, 433-438.
71. Hammond, A.S.; Rodriguez, A.L.; Niswender, C.M.; Lindsley, C.W.; Conn, P.J. Discovery of a novel chemical class of allosteric ligands of metaboropic glutamate receptor subtype 5 indicates distinct modes of efficacy as well as a unique interaction with the receptor'. ACS Chem. Neurosci., 2010, 1, 702-716.
72. Mueller, R.; Rodriguez, A.; Dawson, E.S.; Butkiewicz, M.; Oleskiewicz, S.; Bleckmann, A.; Weaver, C.D.; Lindsley, C.W.; Conn, P.J.; Meiler, J. Identification of metabotropic glutamate receptor subtype 5 potentiators using virtual high-throughput screening. ACS Chem. Neurosci. 2010, 1, 288-305.
73. Williams, R.; Manka, J.T.; Rodriguez, A.L.; Vinson, P.N.; Niswender, C.M.; Weaver, C.D.; Jones, C.K.; Conn, P.J.; Lindsley, C.W.; Stauffer, S.R. Synthesis and SAR of centrally active mGlu5 positive allosteric modulators based on an aryl acetylenic bicyclic lactam scaffold'. Bioorg. Med. Chem. Lett. 2011, 21, 1350-1353.
74. Noetzel, M.J.; Rook, J.M.; Vinson, P.N.; Cho, K.P.; Days, E.; Zhou, Y.; Rodriguez, A.L.; Lavreysen, H.; Stauffer, S.R.; Niswender, C.M.; Xiang, Z.; Daniels, J.S.; Lindsley, C.W.; Weaver, C.D.; Conn, P.J. Functional impact of allosteric agonist activity of selective allosteric modulators of mGlu5 in regulating CNS function. Mol. Pharm. 2012, 81, 120-133.
75. Gregory, K.J.; Noetzel, M.J.; Rook, J.M.; Vinson, P.N.; Stauffer, S.R.; Rodriguez, A.L.; Emmitte, K.A.; Zhou, Y.S.; Manka, J.T.; Felts, A.S.; Chauder, B.A.; Lindsley, C.W.; Niswender, C.M.; Conn, P.J. Investigating mGlu5 allosteric modulator cooperativity, affinity and agonism: enriching structure-function studies and structure-activity relationships. Mol. Pharm. 2012, 82, 860-875.
76. Rodriguez, A.L.; Zhou, Y.; Williams, R.; Venable, D.; Vinson, P.N.; Daniels, J.S.; Dawson, E.S.; Steckler, T.; Laverysen, H.; Mackie, C.; Bartolome, J.M.; MacDonald, G.J.; Niswender, C.M.; Jones, C.K.; Conn, P.J.; Lindsley, C.W.; Stauffer, S.R. Discovery and optimization of a novel series of non-MPEP site mGlu5 PAMs based on an aryl glycine sulfonamide scaffold' Bioorg. Med. Chem. Lett. 2012, 22, 7388-7392.
77. WO2008151184.
78. WO2011035324
79. WO2011149963
80. WO2012031024
81. WO2012078817
82. WO2012083224
83. WO2012092530
84. WO2012097182